Magenta Therapeutics, Inc. (MGTA) |
|
0.6996 -0.059 (-7.74%)
|
09-11 16:00 |
|
Open: |
0.7085 |
Pre. Close: |
0.7583 |
|
High:
|
0.7589 |
Low:
|
0.69 |
|
Volume:
|
375,912 |
Market Cap:
|
42(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 10:18:00 AM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
|
| Target: |
Six months: 0.9 One year: 0.96 |
| Support: |
Support1: 0.68 Support2: 0.57 |
| Resistance: |
Resistance1: 0.77 Resistance2: 0.82 |
| Pivot: |
0.75 |
| Moving Average: |
MA(5): 0.74 MA(20): 0.76
MA(100): 0.73 MA(250): 0.86 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 39.7 %D(3): 51.6 |
| RSI: |
RSI(14): 36.8 |
| 52-week: |
High: 2.06 Low: 0.32 |
| Average Vol(K): |
3-Month: 267 (K) 10-Days: 210 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MGTA ] has closed below the lower bollinger band by 19.5%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 30.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.78 - 0.78 |
0.78 - 0.79 |
|
Low:
|
0.72 - 0.72 |
0.72 - 0.72 |
|
Close:
|
0.75 - 0.76 |
0.76 - 0.77 |
|
Company Description |
|
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Tue, 19 Sep 2023
Metachromatic Leukodystrophy Market to Observe Impressive Growth During the Forecast Period (2023-2032), - Benzinga
Mon, 11 Sep 2023
Why Avantax Shares Are Trading Higher By Over 27%? Here Are ... - Investing.com UK
Mon, 11 Sep 2023
Magenta Therapeutics Announces Completion of Merger with ... - GlobeNewswire
Thu, 31 Aug 2023
North American Morning Briefing : PCE Inflation -2- - 2023-08-31 - Marketscreener.com
Thu, 11 May 2023
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors ... - GlobeNewswire
Wed, 03 May 2023
Magenta Therapeutics and Dianthus Therapeutics Announce ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
61 (M) |
| Shares Float |
34 (M) |
|
% Held by Insiders
|
2.2 (%) |
|
% Held by Institutions
|
62.6 (%) |
|
Shares Short
|
383 (K) |
|
Shares Short P.Month
|
393 (K) |
Stock Financials |
|
EPS
|
-1.15 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.24 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-28.9 |
|
Return on Equity (ttm)
|
-65.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.95 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-73 (M) |
|
Levered Free Cash Flow
|
-30 (M) |
Stock Valuations |
|
PE Ratio
|
-0.61 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.56 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.59 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
